Issues related to patient access, pharmaceutical manufacturing, Patent reform, and drug pricing both domestic and international Issues realted to medicare drug pricing and reimbursement DTC Advertising
2025 · 4th Quarter (Oct 1 - Dec 31)
ABBVIE
Filed by BROWNSTEIN HYATT FARBER SCHRECK, LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 13, 2026
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- BROWNSTEIN HYATT FARBER SCHRECK, LLP
- Client
- ABBVIE
- Filing UUID
- f1599cc2-12fd-47c2-99de-1d2ca4a3863f
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Reciprocal tariffs
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.